Headlands Technologies LLC Has $412,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Headlands Technologies LLC lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 46.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,429 shares of the medical research company’s stock after selling 1,250 shares during the quarter. Headlands Technologies LLC’s holdings in Amgen were worth $412,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Citizens Financial Group Inc. RI lifted its holdings in Amgen by 8.6% during the 4th quarter. Citizens Financial Group Inc. RI now owns 11,943 shares of the medical research company’s stock valued at $3,440,000 after purchasing an additional 943 shares during the last quarter. KFA Private Wealth Group LLC lifted its holdings in Amgen by 7.2% during the 4th quarter. KFA Private Wealth Group LLC now owns 1,428 shares of the medical research company’s stock valued at $411,000 after purchasing an additional 96 shares during the last quarter. Kovack Advisors Inc. lifted its holdings in Amgen by 5.0% during the 4th quarter. Kovack Advisors Inc. now owns 2,983 shares of the medical research company’s stock valued at $859,000 after purchasing an additional 141 shares during the last quarter. Callan Capital LLC lifted its holdings in shares of Amgen by 5.8% during the fourth quarter. Callan Capital LLC now owns 2,506 shares of the medical research company’s stock worth $722,000 after buying an additional 137 shares in the last quarter. Finally, Bahl & Gaynor Inc. lifted its holdings in shares of Amgen by 36.2% during the fourth quarter. Bahl & Gaynor Inc. now owns 606,580 shares of the medical research company’s stock worth $174,707,000 after buying an additional 161,157 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.2 %

Shares of NASDAQ:AMGN traded up $0.60 during midday trading on Friday, hitting $269.98. 2,436,959 shares of the stock were exchanged, compared to its average volume of 2,035,139. The stock has a market capitalization of $144.81 billion, a price-to-earnings ratio of 21.62, a P/E/G ratio of 2.60 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The business’s 50-day moving average price is $275.10 and its 200 day moving average price is $281.45. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.09 earnings per share. Analysts predict that Amgen Inc. will post 19.43 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is currently 72.06%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Raymond James assumed coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating for the company. StockNews.com downgraded Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Royal Bank of Canada reissued an “outperform” rating and set a $329.00 target price on shares of Amgen in a report on Wednesday, April 3rd. The Goldman Sachs Group raised their price target on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Finally, SVB Leerink cut Amgen from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $324.00 to $318.00 in a research report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $296.95.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.